skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study

(2372) Views  (372) Full article downloads

Authors: Jeetesh V Patel, Sandeep Gupta, Frank Lie, Elizabeth A Hughes

Published Date January 2005 Volume 2005:1(4) Pages 351 - 356
DOI: http://dx.doi.org/10.2147/VHRM.S

Jeetesh V Patel1, Sandeep Gupta2, Frank Lie3, Elizabeth A Hughes1

1Sandwell and West Birmingham Hospitals NHS Trust, West Bromwich, UK; 2Whipps Cross and St Bartholomew’s Hospitals; and 3Whipps Cross University Hospital, London, UK

Background: Rates of coronary heart disease (CHD) mortality are 40% higher amongst South Asian men and women living in the UK compared with the general UK population. Despite an established excess CHD risk, little is known of the efficacy and safety of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) amongst South Asian migrants.

Methods and results: Hyperlipidemic South Asian patients (raised or uncontrolled lowdensity lipoprotein cholesterol [LDL-C]) were recruited from two UK centers (n = 33). After a five-week period, which included dietary advice, patients received atorvastatin 10 mg/d for five weeks to achieve a target LDL-C goal of < 3.0 mmol/L, titrated to 20 mg, 40 mg, or 80 mg for a further 12 weeks as required. Significant reductions in LDL-C levels from baseline were observed after 4 weeks’ and 17 weeks’ treatment with atorvastatin (≥ 33.6%; 26.0, 41.2). Overall, 81% (95% confidence interval [CI]: 62.5, 92.6%) achieved the target LDL-C after 4 weeks’ treatment with 10 mg atorvastatin. Titration to a dose of more than 20 mg was required in only one patient (40 mg) at any point during the study. Nineteen patients reported at least one adverse event during the study; the majority were mild in severity and considered unrelated to atorvastatin.

Conclusions: Atorvastatin was effective in achieving target lipid levels and was well tolerated. Statin therapy for high-risk South Asian individuals is likely to benefit CHD outcomes, although further and larger prospective trials are required.

Keywords: hyperlipidemia, lipids, cholesterol, dyslipidemia, statins, coronary heart disease, South Asians








Readers of this article also read:

Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
ABO and rhesus blood group distribution in Kurds
Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits
Corrigendum: Softec HD hydrophilic acrylic intraocular lens: biocompatibility and precision
Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK
Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University